Abstract:Preoperative chemotherapy in LACC patients is safe and able to induce major tumor regression. Survival times are encouraging, and further research seems warranted.
“…Although neoadjuvant chemotherapy is not routinely administered in locally advanced colorectal cancer patients, several authors have demonstrated benefits with a neoadjuvant chemotherapy-alone approach [25,26]. Studies have shown that neoadjuvant chemotherapy with CAPOX or FOLFOX is effective and safe in patients with locally advanced colon cancers [25,26].…”
Background: This study aimed to evaluate the safety and feasibility of self-expanding metallic stent (SEMS) followed by neoadjuvant chemotherapy prior to elective surgery for obstructing left-sided colon cancer. Methods: Eleven consecutive patients with obstructing left-sided colon cancer between May 2014 and November 2015 were included retrospectively. All patients received SEMS followed by neoadjuvant chemotherapy. The primary outcome measure was stoma and laparoscopic surgery. Results: Chemotherapy was with two cycles of CAPOX (54.5%) or three cycles mFOLFOX6 (45.5%). Median serum albumin and hemoglobin levels before surgery were significantly higher than before neoadjuvant chemotherapy (p = 0.01 and p = 0.008 respectively) and before SEMS (p = 0.01 and p = 0.003 respectively). Median bowel wall thickness proximal to the upper edge of tumor was significantly more before neoadjuvant chemotherapy than before stent (p = 0.003), and significantly less before surgery than before neoadjuvant chemotherapy (p = 0.003). No patient underwent stoma creation. Laparoscopic surgery was performed in nine (81.8%) patients. No local recurrence or metastases developed over median cancer-specific follow-up of 44 months (range, 37-55 months). Conclusion: SEMS followed by neoadjuvant chemotherapy prior to elective surgery appears to be safe and well tolerated in patients with obstructing left-sided colon cancer.
“…Although neoadjuvant chemotherapy is not routinely administered in locally advanced colorectal cancer patients, several authors have demonstrated benefits with a neoadjuvant chemotherapy-alone approach [25,26]. Studies have shown that neoadjuvant chemotherapy with CAPOX or FOLFOX is effective and safe in patients with locally advanced colon cancers [25,26].…”
Background: This study aimed to evaluate the safety and feasibility of self-expanding metallic stent (SEMS) followed by neoadjuvant chemotherapy prior to elective surgery for obstructing left-sided colon cancer. Methods: Eleven consecutive patients with obstructing left-sided colon cancer between May 2014 and November 2015 were included retrospectively. All patients received SEMS followed by neoadjuvant chemotherapy. The primary outcome measure was stoma and laparoscopic surgery. Results: Chemotherapy was with two cycles of CAPOX (54.5%) or three cycles mFOLFOX6 (45.5%). Median serum albumin and hemoglobin levels before surgery were significantly higher than before neoadjuvant chemotherapy (p = 0.01 and p = 0.008 respectively) and before SEMS (p = 0.01 and p = 0.003 respectively). Median bowel wall thickness proximal to the upper edge of tumor was significantly more before neoadjuvant chemotherapy than before stent (p = 0.003), and significantly less before surgery than before neoadjuvant chemotherapy (p = 0.003). No patient underwent stoma creation. Laparoscopic surgery was performed in nine (81.8%) patients. No local recurrence or metastases developed over median cancer-specific follow-up of 44 months (range, 37-55 months). Conclusion: SEMS followed by neoadjuvant chemotherapy prior to elective surgery appears to be safe and well tolerated in patients with obstructing left-sided colon cancer.
“…Although neoadjuvant chemotherapy is not routinely administered in locally advanced colorectal cancer patients, several authors have demonstrated benefits with a neoadjuvant chemotherapy-alone approach. 25,26 Studies have shown that neoadjuvant chemotherapy with CAPOX or FOLFOX is effective and safe in patients with locally advanced colon cancers. 25,26 All patients in our study completed neoadjuvant chemotherapy without experiencing any major toxicities.…”
Section: Discussionmentioning
confidence: 99%
“…25,26 Studies have shown that neoadjuvant chemotherapy with CAPOX or FOLFOX is effective and safe in patients with locally advanced colon cancers. 25,26 All patients in our study completed neoadjuvant chemotherapy without experiencing any major toxicities. Although no patient achieved complete pathologic response in our study, tumor reduction was achieved in all patients.…”
BACKGROUND: This study aimed to evaluate the safety and feasibility of self-expanding metallic stent (SEMS) followed by neoadjuvant chemotherapy prior to elective surgery for obstructing left-sided colon cancer.
METHODS: Eleven consecutive patients with obstructing left-sided colon cancer between May 2014 and November 2015 were included retrospectively. All patients received SEMS followed by neoadjuvant chemotherapy. The primary outcome measure was stoma and laparoscopic surgery.
RESULTS: Chemotherapy was with two cycles of CAPOX (54.5%) or three cycles mFOLFOX6 (45.5%). Median serum albumin and hemoglobin levels before surgery were significantly higher than before neoadjuvant chemotherapy (p = 0.01 and p = 0.008 respectively) and before SEMS (p = 0.01 and p = 0.003 respectively). Median bowel wall thickness proximal to the upper edge of tumor was significantly more before neoadjuvant chemotherapy than before stent (p = 0.003), and significantly less before surgery than before neoadjuvant chemotherapy (p = 0.003). No patient underwent stoma creation. Laparoscopic surgery was performed in nine (81.8%) patients. No local recurrence or metastases developed over median cancer-specific follow-up of 44 months (range, 37-55 months).
CONCLUSION: SEMS followed by neoadjuvant chemotherapy prior to elective surgery appears to be safe and well tolerated in patients with obstructing left-sided colon cancer.
“…Although neoadjuvant chemotherapy is not routinely administered in locally advanced colorectal cancer patients, several authors have demonstrated benefits with a neoadjuvant chemotherapy-alone approach. 20,[25][26][27] A single-center phase II study conducted at Memorial Sloan-Kettering Cancer Center evaluated neoadjuvant chemotherapy with six cycles of FOLFOX plus bevacizumab in locally advanced rectal cancer patients and showed that neoadjuvant chemotherapy was relatively safe and capable of inducing major tumor regression. 25 Four cycles of neoadjuvant mFOLFOX6 chemotherapyalone approach has also shown promising efficacy for locally advanced rectal cancer in the FOWARC study.…”
Section: Discussionmentioning
confidence: 99%
“…26 Other studies have shown that neoadjuvant chemotherapy with CAPOX or FOLFOX is effective and safe in patients with locally advanced colon cancers. 20,27 All patients in our study completed neoadjuvant chemotherapy without experiencing any major toxicities. Although no patient achieved complete pathologic response in our study, tumor reduction was achieved in all patients.…”
BACKGROUND: Stoma is reported to be frequent in self-expanding metallic stent (SEMS) treated patients with obstructing left-sided colon cancer than in those with non-obstructing surgery. This study aimed to evaluate the safety and feasibility of SEMS followed by neoadjuvant chemotherapy prior to elective surgery for obstructing left-sided colon cancer. METHODS: Eleven consecutive patients with obstructing left-sided colon cancer between May 2014 and November 2015 were included retrospectively. All patients received SEMS followed by neoadjuvant chemotherapy. The primary outcome measure was stoma and laparoscopic surgery. RESULTS: Chemotherapy was with two cycles of CAPOX (54.5%) or three cycles mFOLFOX6 (45.5%). Median serum albumin and hemoglobin levels before surgery were significantly higher than before neoadjuvant chemotherapy (p = 0.01 and p = 0.008 respectively) and before SEMS (p = 0.01 and p = 0.003 respectively). Median bowel wall thickness proximal to the upper edge of tumor was significantly more before neoadjuvant chemotherapy than before stent (p = 0.003), and significantly less before surgery than before neoadjuvant chemotherapy (p = 0.003). No patient underwent stoma creation. Laparoscopic surgery was performed in nine (81.8%) patients. No local recurrence or metastases developed over median cancer-specific follow-up of 44 months (range, 37-55 months). CONCLUSION: SEMS followed by neoadjuvant chemotherapy prior to elective surgery appears to be safe and well tolerated in patients with obstructing left-sided colon cancer.NCT02972541; retrospectively registered
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.